Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.49 |
| ▸ | TACR3 | P29371 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | EED | O75530 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | PPID | Q08752 | 1/20 | 0.40 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.39 |
| ▸ | CCR3 | P51677 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31324479 | 0.87 | TACR3 (0.62) | HSD11B1TACR3MEN1KMT2ACARM1 | |
| SCHEMBL4957233 | 0.86 | ALDH1A1 (0.51) | HSD11B1TACR3MEN1KMT2ACCR3 | |
| SCHEMBL21358908 | 0.86 | ALDH1A1 (0.51) | HSD11B1TACR3MEN1KMT2ACCR3 | |
| SCHEMBL28131904 | 0.86 | EPHX2 (0.56) | HSD11B1TACR3EPHX2 | |
| SCHEMBL31326493 | 0.86 | HSD11B1 (0.49) | HSD11B1TACR3EPHX2 | |
| SCHEMBL23234101 | 0.85 | TACR3 (0.44) | TACR3MEN1KMT2ACCR3 | |
| SCHEMBL27953755 | 0.82 | MEN1 (0.54) | MEN1KMT2ACCR3 | |
| SCHEMBL28922174 | 0.82 | EPHX2 (0.47) | HSD11B1TACR3EEDEPHX2CCR3 | |
| SCHEMBL5582903 | 0.81 | BACE1 (0.50) | MEN1KMT2A | |
| SCHEMBL27177263 | 0.80 | KMT2A (0.53) | HSD11B1TACR3MEN1KMT2ACARM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070173498-A1 | Melanin concentrating hormone antagonist | KATO KANEYOSHI | 2007-07-26 | — | — | US | disclosed |
| US-7115750-B1 | Melanin concentrating hormone antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-10-03 | — | — | US | disclosed |
| EP-1218336-A2 | MELANIN CONCENTRATING HORMONE ANTAGONIST | Takeda Chemical Industries, Ltd. (JP) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001021577-A2 | MELANIN CONCENTRATING HORMONE ANTAGONIST | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173498-A1 | Melanin concentrating hormone antagonist | MC1R, MCHR1, MCHR2 | HSD11B1 105/4885TACR3 815/4885MEN1 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.